We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+19.66%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$940M
AUM Growth
-$118M
Cap. Flow
-$198M
Cap. Flow %
-21.11%
Top 10 Hldgs %
62.65%
Holding
57
New
1
Increased
–
Reduced
32
Closed
9

Top Buys

Rank Stock Value
1
HNGE
Hinge Health
HNGE
+$12.1M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$53.9M
2
SRRK icon
Scholar Rock
SRRK
+$14.7M
3
BSX icon
Boston Scientific
BSX
+$10.9M
4
KRYS icon
Krystal Biotech
KRYS
+$10.9M
5
COGT icon
Cogent Biosciences
COGT
+$9.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BNTX icon
51
BioNTech
BNTX
$25.6B
– –
-73,071
Closed -$6.65M
CYTK icon
52
Cytokinetics
CYTK
$10B
– –
-82,098
Closed -$3.3M
IMVT icon
53
Immunovant
IMVT
$8.51B
– –
-490,394
Closed -$8.38M
IRTC icon
54
iRhythm Holdings
IRTC
$3.96B
– –
-56,844
Closed -$5.95M
MASI
55
DELISTED
Masimo
MASI
– –
-26,062
Closed -$4.34M
PODD icon
56
Insulet
PODD
$10.1B
– –
-27,109
Closed -$7.12M
ORKA
57
Oruka Therapeutics
ORKA
$6.03B
– –
-386,963
Closed -$3.97M
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2025 Portfolio in Review

As of Q2 2025, Redmile Group held 57 positions worth $940M, down 11% from $1.06B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Redmile Group withdrew a net $198M in Q2 2025, closing 9 positions and reducing 32 holdings. Its most notable exit was Immunovant, an estimated $8.38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Redmile Group opened a new position in Hinge Health worth $15.5M.

  • Redmile Group's largest Q2 2025 buy was Hinge Health: 300,000 shares worth $15.5M.
  • Redmile Group's biggest Q2 2025 reduction was Amicus Therapeutics, cutting an estimated $53.9M.
  • Redmile Group fully exited Immunovant in Q2 2025, selling an estimated $8.38M.
  • Redmile Group's ten largest holdings make up 63% of its $940M portfolio in Q2 2025.
  • Redmile Group opened 1 new position and closed 9 in Q2 2025.
  • Redmile Group's portfolio value fell 11% quarter-over-quarter to $940M.

Based on Redmile Group's 13F filing for Q2 2025, filed 14 Aug 2025.